Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

1.83
-0.0600-3.17%
Post-market: 1.840.0100+0.55%19:55 EDT
Volume:890.93K
Turnover:1.61M
Market Cap:77.30M
PE:-2.87
High:1.94
Open:1.90
Low:1.75
Close:1.89
52wk High:4.34
52wk Low:1.41
Shares:42.24M
Float Shares:40.90M
Volume Ratio:1.46
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6370
EPS(LYR):-0.8920
ROE:-155.66%
ROA:-66.93%
PB:4.16
PE(LYR):-2.05

Loading ...

Gain Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 26

Gain Therapeutics Q4 EPS $(0.11) Beats $(0.17) Estimate.

Benzinga
·
Mar 26

Gain Therapeutics FY2025 net loss per share narrows 31.46% to $0.61; cash, cash equivalents and marketable securities climb more than doubled to $20.8 million

Reuters
·
Mar 26

Gain Therapeutics Inc - 2025 Net Loss $20.2 Mln, or $0.61 per Share

THOMSON REUTERS
·
Mar 26

Gain Therapeutics Inc - Clearance of Ind Submission to FDA for Phase 2 of GT-02287 Expected in 2Q26

THOMSON REUTERS
·
Mar 26

Press Release: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Dow Jones
·
Mar 26

Gain Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
Mar 23

Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX)

TIPRANKS
·
Mar 21

Gain Therapeutics CEO to join fireside chat at ROTH Conference

Reuters
·
Mar 20

Gain Therapeutics Reports Promising GT-02287 Parkinson’s Data

TIPRANKS
·
Mar 18

Gain Therapeutics reports Phase 1b GT-02287 Parkinson’s data showing CSF DDC reduction at 90 days and stable MDS-UPDRS at day 150

Reuters
·
Mar 18

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

GlobeNewswire
·
Mar 18

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 18

Analysts’ Top Healthcare Picks: Gain Therapeutics (GANX), Relmada Therapeutics (RLMD)

TIPRANKS
·
Mar 14

Gain Therapeutics to present Phase 1b GT-02287 data at AD/PD 2026 conference

Reuters
·
Mar 12

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

GlobeNewswire
·
Mar 12

Gain Therapeutics Showcases Allosteric Small Molecule Therapies at J.P. Morgan Healthcare Conference Week

Reuters
·
Jan 07

Gain Therapeutics Announces Announces Conference Participation During J.p. Morgan Healthcare Conference Week

THOMSON REUTERS
·
Jan 07

Gain Therapeutics Reports Positive Phase 1b Results for GT-02287 in Parkinson's Disease

Reuters
·
Jan 06

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

GlobeNewswire
·
Jan 06